PerkinElmer and EverlyWell Announce Collaboration to Expand U.S. At-Home Health Test Market

PerkinElmer, Inc. and EverlyWell, Inc. have announced a new collaboration designed to accelerate innovation in and accessibility of consumer-initiated health testing, by adding PerkinElmer’s CLIA-certified and CAP-accredited lab facilities to EverlyWell’s network of laboratory providers.

The first offerings resulting from this collaboration are Lyme disease and food sensitivity tests, for which PerkinElmer provides the expertise behind EverlyWell’s panels.

Both tests employ dried blood spot testing—a method that has been used for decades by doctors and hospitals to identify disease biomarkers with only a few drops of blood—and were developed by board-certified medical geneticists at PerkinElmer Genomics, then validated on the EUROIMMUN EUROBlotOne® system and EUROIMMUN Analyzer™ systems.

PerkinElmer has long been recognized as a worldwide leader in dried blood spot testing, notably in its industry-leading work with newborn screening. Over 600 million newborn babies worldwide have been screened for life-threatening diseases using PerkinElmer’s dried blood spot testing solution. PerkinElmer’s EUROIMMUN products are also widely recognized as expert solutions for autoimmune, infectious disease, allergy and molecular genetic testing.

Together, the two companies will work to expand EverlyWell’s test menu, bringing additional panels to market.